Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Major Adverse Cardiovascular Events in Adults With Type 2 Diabetes Escalating to Semaglutide 2.0 mg vs Switching to Tirzepatide

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Diabetes
Congress short oral presentation
GLP-1 RA
Semaglutide
RWE